Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has issued an announcement.
Simcere Pharmaceutical Group Limited has announced the acquisition of the entire assets of Sanroad Shanghai and the entire equity interest in Xianwei for a total cash consideration of RMB83,183,800. This strategic move will result in Xianwei becoming an indirectly wholly-owned subsidiary, with its financial results consolidated into Simcere’s financial statements, enhancing the company’s operational scope and market positioning.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating within the pharmaceutical industry. It focuses on the acquisition and development of pharmaceutical assets and equity interests to enhance its market position.
Average Trading Volume: 21,796,197
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.63B
For an in-depth examination of 2096 stock, go to TipRanks’ Overview page.